Is there a generic version of alirocumab yet?
Alirocumab is the active ingredient in Praluent (alirocumab), a PCSK9 inhibitor used to lower LDL cholesterol. There is no widely available “generic Praluent” version reported in the provided information.
Has the Praluent (alirocumab) patent expired?
The provided information does not include patent or exclusivity status for alirocumab, so it’s not possible to confirm whether generics can enter the market based on patent expiry.
Are biosimilars or “follow-on” versions possible instead of a generic?
Alirocumab is a monoclonal antibody, and follow-on products in this category are typically handled through biosimilar pathways rather than the standard small-molecule “generic” pathway. The provided information does not specify whether any biosimilar/alternate versions are approved or expected.
What can patients do if they need a lower-cost alternative?
If no generic/biosimilar versions are available, lower-cost options often come from insurance coverage decisions, prior authorization, copay assistance programs, or switching to an alternative branded therapy in the same class. The provided information does not list specific alternatives or pricing details.
What’s the quickest way to verify availability where you live?
Check your country’s drug registry (or pharmacy availability) for approved biosimilars and generics of “alirocumab” or “Praluent.” The provided information does not include location-specific approvals.
Sources
No sources were provided with the question.